J Korean Diabetes > Volume 20(2); 2019 > Article
The Journal of Korean Diabetes 2019;20(2):81-86.
DOI: https://doi.org/10.4093/jkd.2019.20.2.81    Published online July 17, 2019.
Sodium-Glucose Cotransporter 2 억제제의 심혈관 질환 예방 효과 유발 기전
The Potential Cardioprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors.
Jae Han Jeon
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. jeonjh@knu.ac.kr
The potential mechanism by which sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent cardiovascular disease (CVD) is being widely investigated. Improved insulin resistance, along with decreased body fat mass associated with SGLT2 inhibitor treatment is consistent with previously well-established factors contributing to the prevention of CVD. These factors are responsible for reduction of oxidative stress as well as improvement of systemic inflammation. Because heart failure was one of the most dramatically improved cardiovascular events in various clinical trials and because SGLT2 inhibitors promote osmotic diuresis and natriuresis, hemodynamic changes are considered as a critical mechanism responsible for the cardioprotective effect of SGLT2 inhibitors. Restored tubuloglomerular feedback by SGLT2 inhibitors might play a role in renoprotection, which in turn, leads to fewer CVDs. Finally, blood ketone body increments in response to SGLT2 inhibition might act as a “super-fuel” for salvaging the failing diabetic heart.
Key Words: Cardiovascular diseases, Diabetes mellitus, Ketones, Sodium-glucose transport proteins

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer